Status:
ACTIVE_NOT_RECRUITING
An Observational Study to Learn More About the Safety of Rivaroxaban in Participants With Peripheral Arterial Disease Who Had Surgery to Improve Blood Flow to Their Legs
Lead Sponsor:
Bayer
Conditions:
Peripheral Arterial Disease (PAD)
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study in which data already collected from people with peripheral arterial diseases (PAD) who had a surgery to improve blood flow to their legs are studied. The study is cond...
Eligibility Criteria
Inclusion
- Diagnosed with PAD in or before the month following the index date
- Lower limb revascularization was performed in or before the month of PAD diagnosis
- Age 18 years or older as of the index date
Exclusion
- Lower limb revascularization performed in the same month or before the month of PAD diagnosis was performed after the index date
- Index date before the start date of the enrollment period
Key Trial Info
Start Date :
August 12 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2025
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT07142655
Start Date
August 12 2025
End Date
October 31 2025
Last Update
October 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Data Vision Co., Ltd
Tokyo, Japan, 101-0053